Core Insights - BriaCell Therapeutics Corp. reports significant infiltration of CD8+ "killer" T cells into metastatic breast cancer tumors and lymphatic tissues, indicating a positive response to the Bria-IMT™ plus immune checkpoint inhibitor (CPI) treatment [1][6][7] - The use of CD8 ImmunoPET imaging technology has been validated as a precision diagnostic tool to monitor immune responses in patients, correlating with clinical benefits and tumor marker reductions [2][7] Group 1: Treatment Efficacy - The Bria-IMT™ plus CPI regimen led to the transformation of "cold" tumors into "hot" tumors, suggesting enhanced immune activity against cancer cells [6][7] - In a study involving six patients, 50% showed a decrease in the neutrophil/lymphocyte ratio, indicating immune system activation after treatment [6] Group 2: Imaging Technology - CD8 ImmunoPET imaging was utilized to document the mechanism of action of the Bria-IMT™ regimen, providing insights into its effectiveness in cancer treatment [3][4] - The imaging technology is crucial for identifying pseudo progression in patients who exhibit clinical benefits, distinguishing them from those with actual tumor progression [2][7] Group 3: Clinical Presentation - The findings were presented at the 2024 San Antonio Breast Cancer Symposium, highlighting the potential of the Bria-IMT™ regimen in improving patient outcomes [5][7] - The poster presentation included details such as the abstract number SESS-1069 and emphasized the importance of CD8+ T cells in cancer detection and destruction [5]
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer